Glycyl-alanyl-lysine-L-leucine

Glycyl-Alanyl-Lysine-L-Leucine (Gly-Ala-Lys-Leu): A Reference Overview

Preamble: Scope and Evidence Limitations

Glycyl-alanyl-lysine-L-leucine is a synthetic tetrapeptide that appears in commercial dietary supplement ingredient lists, most prominently in sports nutrition products. Before examining any claimed properties, it is essential to establish the state of the primary literature: as of June 2026, no peer-reviewed clinical trial, systematic review, pharmacopeial monograph (USP, European Pharmacopoeia, WHO, ESCOP, German Commission E), or entry in the NIH Office of Dietary Supplements Dietary Supplement Label Database addresses glycyl-alanyl-lysine-L-leucine as a defined, isolated compound with studied biological activity. The peptide sequence Gly-Ala-Lys-Leu does not appear as a named subject in PubMed/MEDLINE, the Cochrane Library, or EFSA scientific opinion databases. What the published literature does support is knowledge about the four constituent amino acids individually and about small bioactive peptides as a general class, and this article draws exclusively from those verified sources. Claims that go beyond what verified sources support are noted as unverified.

Identity and Chemical Characterization

Nomenclature

Glycyl-alanyl-lysine-L-leucine is a synthetic peptide comprised of the amino acids glycine, alanine, lysine, and leucine. In standard peptide chemistry nomenclature, the sequence is written N-terminus to C-terminus as Gly-Ala-Lys-Leu, using the three-letter amino acid abbreviation system, or G-A-K-L in single-letter code. The designation "L-leucine" at the C-terminus specifies the naturally occurring L-stereoisomer of leucine; lysine in biological peptides is similarly understood to be L-lysine unless otherwise stated.

Chemical Nature

As a tetrapeptide, glycyl-alanyl-lysine-L-leucine is a member of the broader class of oligopeptides. This compound belongs to the broader class of oligopeptides and shares structural similarities with other di- and tripeptides derived from proteinogenic amino acids. All four of its constituent amino acids are proteinogenic — meaning they are encoded by the standard genetic code and are the building blocks of naturally occurring proteins in living organisms.

The four residues confer distinct physicochemical properties to the peptide:

• Glycine (Gly, G): The smallest amino acid, with no chiral center and a hydrogen as its side chain. The inclusion of leucine confers hydrophobicity, while glycine enhances flexibility.
• Alanine (Ala, A): A small, nonpolar amino acid with a methyl side chain.
• Lysine (Lys, K): A positively charged, polar essential amino acid under physiological pH conditions, contributing a cationic character to the peptide.
• L-Leucine (Leu, L): A branched-chain amino acid (BCAA) that is hydrophobic, contributing to reduced overall water solubility of the tetrapeptide.

Glycyl-alanyl-leucine (a related tripeptide) is moderately soluble in water due to the glycine residue but less soluble than purely polar peptides such as glycyl-glycine. By analogy, the addition of a lysine residue — which is strongly polar and positively charged — to the sequence is expected to improve aqueous solubility relative to sequences containing only hydrophobic residues, though no direct solubility data for the exact Gly-Ala-Lys-Leu sequence has been retrieved from authoritative sources.

Synthesis

No natural dietary or botanical source of the specific tetrapeptide sequence Gly-Ala-Lys-Leu has been identified in the scientific literature. Glycyl-alanyl-L-leucine (a related synthetic tripeptide) is not a naturally occurring peptide; its constituent amino acids are essential building blocks in human nutrition and metabolism. The same reasoning applies to Gly-Ala-Lys-Leu: it is a synthetic construct prepared by standard peptide chemistry. Such peptides can be synthesized through standard peptide synthesis techniques, involving the stepwise addition of protected amino acids to a growing peptide chain, typically starting with the protection of amino and carboxyl groups to prevent unwanted side reactions.

Traditional and Historical Use

There is no documented traditional or historical use of glycyl-alanyl-lysine-L-leucine as a defined compound in any medical tradition. This specific peptide is not a naturally occurring peptide; its constituent amino acids are essential building blocks in human nutrition and metabolism. The peptide as an isolate is a product of modern synthetic chemistry and has no documented presence in Ayurvedic, Traditional Chinese, Greek, Arabic, African, or Indigenous American medicinal systems. While the specific peptide sequence is a modern development, the amino acids it contains have a long and rich history in both traditional and modern medicine.

The historical context that can be legitimately attributed relates to high-protein foods: this specific tetrapeptide does not have a documented history as a traditional medicinal remedy in ancient texts; however, its constituent amino acids have long been recognized for their vital roles in human health and nutrition. Historically, foods rich in these amino acids — such as legumes, grains, and meats — have been valued in various cultures for their restorative and nourishing properties, often incorporated into broths, tonics, and healing diets to promote recovery and vitality. These historical practices, however, involved the full complement of dietary proteins and were not directed at any specific peptide sequence.

Key Constituent Amino Acids and Established Biochemistry

Because no direct mechanistic research on glycyl-alanyl-lysine-L-leucine itself has been located in authoritative sources, the following section describes the well-characterized biochemistry of its four constituent amino acids as established in the peer-reviewed literature. These mechanisms cannot be automatically attributed to the intact tetrapeptide without studies specifically examining that compound.

Glycine

Glycine is the most important and simplest nonessential amino acid in humans, animals, and many mammals. Its biochemical roles are unusually diverse. Glycine has multiple roles in many reactions such as gluconeogenesis, purine, haem, and chlorophyll synthesis, and bile acid conjugation. It is also used in the formation of many biologically important molecules. The sarcosine component of creatine is derived from glycine and S-adenosylmethionine.

Glycine is of particular importance in the structure of collagen: collagen, the most widespread protein in animals, contains glycine as every third amino acid. This regular repetition of glycine residues is required for the tight packing of the collagen triple helix. Glycine, which is 33% of collagen residues, has been typically classified as a "non-essential" amino acid because human metabolism can synthesize it from serine. However, research has demonstrated that the biosynthetic pathway has stoichiometric limitations, suggesting that dietary glycine may be conditionally important for collagen production. Glycine, proline, and lysine play a special role in collagen structure, and their insufficient availability could be a cause to make collagen synthesis and regeneration difficult.

Glycine also has immunomodulatory properties: tumor necrosis factor, inflammation, and activation of macrophages are inhibited by glycine. Glycine also reduces alcohol-induced liver damage and removes lipid peroxidation reperfusion injury and glutathione deficiency caused by several types of hepatotoxins. Additionally, glycine lowers the level of superoxide ions from neutrophils through glycine-gated chloride channels.

Alanine

Alanine and glutamine are the principal glucogenic amino acids. Alanine plays a significant role during early starvation, exposure to high-fat and high-protein diets, and diabetes. In muscle physiology, the glucose-alanine cycle is a well-established pathway in which alanine is synthesized in skeletal muscle from pyruvate (using amino groups donated by branched-chain amino acid catabolism) and transported to the liver, where it serves as a precursor for gluconeogenesis. Glycine along with alanine show special character to improve alcohol metabolism.

Lysine

Lysine is an essential amino acid — one that cannot be synthesized de novo by the human body and must be obtained from diet or supplementation. Its role in collagen metabolism is well established: lysyl oxidase, a copper-dependent enzyme, acts on lysine and hydroxylysines, and covalent bonding between tropocollagen molecules forms a collagen fibril. This cross-linking step is critical to the tensile strength of mature collagen. Lysine plays a special role in collagen structure, and its insufficient availability could be a cause to make collagen synthesis and regeneration difficult.

L-Leucine

Of the four constituent amino acids of this peptide, L-leucine has the most extensively characterized role in muscle protein metabolism. Leucine is a branched-chain amino acid and a potent activator of the mTOR (mechanistic target of rapamycin) signaling pathway. Leucine activates the signaling factor of mammalian target of rapamycin (mTOR) to promote protein synthesis in skeletal muscle and in adipose tissue.

Ingestion of a leucine-enriched essential amino acid nutrient solution rapidly and potently activates the mammalian target of rapamycin (mTOR) signaling pathway and protein synthesis in human skeletal muscle. Further, mTOR signaling and muscle protein synthesis are enhanced when leucine-enriched nutrients are ingested following resistance exercise.

Animal research has elucidated the mechanistic cascade: to elucidate the molecular mechanism by which leucine stimulates protein synthesis in neonatal muscle, piglets treated with rapamycin (an inhibitor of mTORC1) and then infused with leucine showed that rapamycin completely blocked leucine-induced muscle protein synthesis. Rapamycin blocked the leucine-induced phosphorylation of mTOR, S6 kinase 1 (S6K1), and eukaryotic initiation factor (eIF)4E-binding protein-1 (4E-BP1) and formation of the eIF4E·eIF4G complex. These findings confirm mTORC1 as the primary mediator of leucine's anabolic signaling.

The effects of amino acid intake on protein synthesis in the intact rat appear to be mediated almost entirely by a single amino acid: leucine. The effect of leucine on protein synthesis appears to be closely associated with eIF4G phosphorylation and its association with eIF4E.

It is important to note that the above mechanisms describe free L-leucine or leucine-enriched whole protein solutions — not the Gly-Ala-Lys-Leu tetrapeptide itself. Whether intact delivery of leucine within the context of this specific tetrapeptide activates mTOR in the same manner as free leucine has not been established in the literature.

Intestinal Absorption of Small Peptides: General Class Mechanisms

One argument commonly made for synthetic peptide supplements of this type is that peptide-form delivery confers absorption advantages. The scientific literature does support the existence of a highly efficient intestinal peptide transport system, though this has not been directly studied for Gly-Ala-Lys-Leu specifically.

The intestinal peptide transporter 1 (PepT1) was first identified in 1994. It plays a crucial role in the absorption of small peptides including not only more than 400 different dipeptides and 8,000 tripeptides digested from dietary proteins, but also a repertoire of structurally related compounds and drugs.

The proton-coupled uptake of the more than 8,000 different di- and tripeptides is performed by the high-capacity/low-affinity peptide transporter isoform PEPT1 (SLC15A1). Critically, PepT1 is characterized as a transporter for di- and tripeptides; tetrapeptides such as Gly-Ala-Lys-Leu are not confirmed substrates of PepT1. Enzymatic hydrolysis of dietary proteins to short-chain peptides by pancreatic and intestinal brush-border peptidases can cause the release of up to 400 different dipeptides and up to 8,000 different tripeptides. These peptides, which cover a range of molecular masses from 96.2 Da (diglycine) to 522.6 Da (tritryptophan), are all substrates of the intestinal high-capacity low-affinity peptide transporter PEPT1.

Bioactive di/tripeptides are among the most efficient structural units that can cross the intestinal barrier and reach the circulation, owing to their small molecular size and compact conformation. Evidence indicates that more than 70% of protein digestion products in the gastrointestinal tract are absorbed in the form of di/tripeptides, primarily via a specialized proton-coupled transport system. This means that if the Gly-Ala-Lys-Leu tetrapeptide reaches the intestinal lumen, it would likely require hydrolysis to smaller fragments before efficient PepT1-mediated absorption could occur. Whether this hydrolysis preserves any putative biological activity of the intact tetrapeptide is unknown.

Scientific Evidence by Area of Use

Important overarching qualification: The following section reviews evidence as it pertains to the constituent amino acids or to structurally related small peptides as a general class, since no direct clinical evidence exists for Gly-Ala-Lys-Leu. Evidence strength for this specific compound across all areas is absent to negligible at the level of human clinical research.

Skeletal Muscle Protein Synthesis and Sports Performance

The most prominent commercial claim for this tetrapeptide is support of muscle protein synthesis and athletic recovery. The rationale rests on the leucine content and on the general category of bioactive peptides in sports nutrition.

Bioactive peptides are physiologically active peptides mostly derived from proteins following gastrointestinal digestion, fermentation, or hydrolysis by proteolytic enzymes. It has been shown that bioactive peptides can be resorbed in their intact form and have repeatedly been shown to have a positive effect on health-related parameters such as hypertension, dyslipoproteinemia, inflammation, and oxidative stress.

In recent years, there has been increasing evidence that biologically active peptides could also play an important role in sports nutrition. Current studies have shown that bioactive peptides could have a positive impact on changes in body composition and muscular performance, reduce muscle damage following exercise, and induce beneficial adaptations within the connective tissue.

However, this evidence base applies to the general class of food-derived bioactive peptides, not to Gly-Ala-Lys-Leu specifically. The evidence for this particular compound in sport is limited to marketing materials, none of which are peer-reviewed. The field of bioactive peptides in sports nutrition faces significant new challenges, including the lack of standardized dosages, unmapped structure-activity relationships, and a scarcity of human clinical trials.

The addition of leucine to regular meals may improve the ability of feeding to stimulate protein synthesis in old human muscle — but this finding pertains to free leucine, not to Gly-Ala-Lys-Leu. Furthermore, a key animal study note of caution: when protein and energy intakes are restricted for 8 days, leucine supplementation increases muscle mTOR activation but does not improve body weight gain or enhance skeletal muscle protein synthesis in neonatal pigs. This illustrates that leucine-based mTOR activation does not automatically translate to measurable muscle anabolism across all contexts.

Evidence strength for Gly-Ala-Lys-Leu specifically in muscle performance: None (no human clinical trials identified).

Connective Tissue and Wound Healing

Glycine and lysine, two of the four constituent amino acids, have individually documented roles in collagen biochemistry. Lysyl oxidase, a copper-dependent enzyme, acts on lysine and hydroxylysines, and covalent bonding between tropocollagen molecules forms a collagen fibril. Collagen, the most widespread protein in animals, contains glycine as every third amino acid. This regular repetition of glycine residues is required for the tight packing of the collagen triple helix.

In wound healing contexts, collagen synthesis rates rise dramatically: collagen synthesis rate was increased by 480% and 860% on days 2 and 7 respectively after surgery in wounded rat muscle compared with an undamaged area of the same muscle. These results demonstrate that collagen deposition during wound healing in muscle is achieved entirely by an increase in the rate of collagen synthesis. These findings support the physiological importance of amino acid substrate availability for wound repair, but do not specifically implicate the Gly-Ala-Lys-Leu tetrapeptide.

Evidence strength for Gly-Ala-Lys-Leu specifically in connective tissue/wound healing: None (indirect constituent amino acid biochemistry only).

Immune Function

Glycine and lysine both have connections to immune function. Tumor necrosis factor, inflammation, and activation of macrophages are inhibited by glycine. Glycine lowers the level of superoxide ions from neutrophils through glycine-gated chloride channels. These immunomodulatory properties are attributed to free glycine acting on specific receptor systems; the relevance of these mechanisms to the intact Gly-Ala-Lys-Leu tetrapeptide is speculative.

Evidence strength for Gly-Ala-Lys-Leu specifically in immune function: None (constituent amino acid data only).

Gluconeogenesis and Energy Metabolism

Alanine and glycine both participate in gluconeogenic pathways. Alanine and glutamine are the principal glucogenic amino acids. Most originate from muscles, where branched-chain amino acids (valine, leucine, and isoleucine) are nitrogen donors. Alanine plays a significant role during early starvation, exposure to high-fat and high-protein diets, and diabetes. These are fundamental metabolic roles of the free amino acid, not demonstrated functions of the specific tetrapeptide.

Evidence strength for Gly-Ala-Lys-Leu specifically in glucose metabolism: None (constituent amino acid biochemistry only).

Commercial Forms and Supplement Context

Multiple dietary supplements have been identified as containing glycyl-alanyl-lysine-L-leucine as a listed ingredient. The synthetic peptide's inclusion in contemporary nutritional supplements is inspired by long-standing traditions around high-protein diets. Often, it is combined with herbal adaptogens, antioxidants, and vitamins to maximize putative restorative effects, particularly in sports nutrition and recovery blends.

The compound is most consistently found in sports protein powders, amino acid blends, and post-workout recovery formulas, where it appears alongside other di-, tri-, and tetrapeptides in proprietary blends. No standardized or pharmacopeial dosage form or specification exists for this peptide. No dosage information for Gly-Ala-Lys-Leu specifically appears in any peer-reviewed publication, government database, or official dietary supplement monograph retrieved in this review. Reporting a specific milligram dosage would therefore not be verifiable from authoritative sources and is omitted in accordance with the accuracy standards of this article.

Relationship to Other Studied Tetrapeptides

To contextualize glycyl-alanyl-lysine-L-leucine within the broader science of tetrapeptides, it is instructive to note that other tetrapeptide sequences have been the subjects of direct scientific investigation — though not Gly-Ala-Lys-Leu itself. For example:

• Tetrapeptide Ala-Asp-Glu-Leu (ADEL) was effective on models of acute bacterial lung inflammation, fibrosis, and toxic lung damage in several studies.
• Tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly were synthesized on the basis of amino acid composition of pituitary cytomedins. Administration of these tetrapeptides to hypophysectomized chickens for 40 days was followed by an increase in the concentrations of thyrotropic hormone and thyroid hormones and recovery of thyroid gland structure.
• The L-Ala-L-Glu-L-Asp-Gly tetrapeptide showed properties in pre-clinical experiments relevant to a geroprotective application.

These examples demonstrate that specific tetrapeptide sequences can have measurable, sequence-dependent biological effects in animal and cell-culture studies. However, the bioactivity of one tetrapeptide cannot be generalized to another; the specific sequence of amino acids determines function, and the Gly-Ala-Lys-Leu sequence has not undergone this kind of characterization in the published literature.

Safety Considerations

No clinical safety data specific to glycyl-alanyl-lysine-L-leucine has been identified in peer-reviewed literature, regulatory agency databases, or pharmacopeial monographs. The following observations are grounded solely in what can be verified from authoritative sources.

General Safety of Short Synthetic Peptides

Some studies have shown that peptides have high treatment potential due to their biological activity, harmlessness, and tissue-specific action — this is a general observation about small peptides that has been made in the context of regulatory or pre-clinical assessments of other defined peptide compounds, not of Gly-Ala-Lys-Leu specifically. Human clinical trials on peptide compounds for recovery are limited. Most evidence comes from animal studies. Claims online often go far beyond what research supports.

Constituent Amino Acid Safety

The four constituent amino acids — glycine, alanine, lysine, and leucine — are normal dietary amino acids found in all protein-containing foods and are generally recognized as safe (GRAS) at nutritional doses. However, the safety profile of their combination in a specific synthetic tetrapeptide at supplement doses has not been independently characterized.

Absence of Allergen or Interaction Data

No peer-reviewed publications, government agency advisories (FDA, EFSA, Health Canada), or pharmacopeial documents have been retrieved that document drug interactions, contraindications, or adverse event patterns for Gly-Ala-Lys-Leu. The absence of documented adverse events should not be interpreted as evidence of safety in the absence of any systematic human safety assessment.

Regulatory Status

In the United States, this compound, when sold as a dietary supplement ingredient, is not subject to pre-market approval by the FDA. It is not listed in the FDA's list of Generally Recognized as Safe (GRAS) substances as an isolated synthetic tetrapeptide, nor does it appear in the European Food Safety Authority's (EFSA) Novel Food catalogue as an evaluated ingredient.

Critical Appraisal: What the Evidence Does and Does Not Support

The table below summarizes the evidence landscape for glycyl-alanyl-lysine-L-leucine as a dietary supplement ingredient:

• Chemical identity: Well-characterized as a synthetic tetrapeptide composed of glycine, alanine, lysine, and L-leucine. ✓ (supported by basic chemistry)
• Natural occurrence: No identified natural source for this specific sequence. ✗ (not found in authoritative sources)
• Traditional use: None documented for this specific peptide. ✗
• In vitro biological activity data: None identified in authoritative sources for this specific sequence. ✗
• Animal study data: None identified for this specific sequence. ✗
• Human clinical trials: None identified. ✗
• Established dosage: None from peer-reviewed or regulatory sources. ✗
• Pharmacopeial monograph: None. ✗
• Constituent amino acid biochemistry: Extensively characterized individually in the peer-reviewed literature. ✓
• PepT1 transport as a tetrapeptide: Not established; PepT1 is characterized for di- and tripeptides. ✗

Direct clinical studies on closely related synthetic peptides are limited; evidence from related peptides is what supports their use in nutritional products. This characterization applies with particular force to glycyl-alanyl-lysine-L-leucine, for which even the broader evidence base of analogous studied sequences is largely absent. The ingredient appears to have been introduced into commercial products ahead of any independent scientific validation of its specific efficacy or safety as an isolated compound.

References

• Drummond MJ, Rasmussen BB. "Leucine-Enriched Nutrients and the Regulation of mTOR Signalling and Human Skeletal Muscle Protein Synthesis." PMC / Current Opinion in Clinical Nutrition and Metabolic Care, 2008.
• Duan Y et al. "Leucine nutrition in animals and humans: mTOR signaling and beyond." PubMed / Amino Acids, 2016.
• Norton LE, Layman DK. "Leucine and protein synthesis: mTOR and beyond." PubMed / Nutrition Reviews, 2006.
• Davis TA et al. "Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation." PMC / American Journal of Physiology-Endocrinology and Metabolism, 2008.
• El-Kadi SW et al. "Leucine supplementation of a chronically restricted protein and energy diet enhances mTOR pathway activation but not muscle protein synthesis in neonatal pigs." PubMed / Journal of Nutrition, 2015.
• Liu L et al. "Regulation profile of the intestinal peptide transporter 1 (PepT1)." PMC / Drug Metabolism Reviews, 2017.
• Review: "Intestinal epithelial transport of bioactive di/tripeptides through PepT1: Molecular mechanism and influencing factors." ScienceDirect / Food Chemistry, 2025.
• Brandsch M. "Transcriptional and functional regulation of the intestinal peptide transporter PEPT1." PMC / Current Opinion in Pharmacology, 2009.
• Groneberg DA et al. "Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1." American Journal of Physiology-Gastrointestinal and Liver Physiology, 2001.
• Razak MA et al. "Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review." PMC / Oxidative Medicine and Cellular Longevity, 2017.
• de Paz-Lugo P et al. "High glycine concentration increases collagen synthesis by articular chondrocytes in vitro." PMC / Amino Acids, 2018.
• Kasznel AJ et al. "The irreplaceable glycine: glycine homologs destabilize the collagen triple helix." ScienceDirect / Tetrahedron, 2024.
• Protein GS et al. "Biochemistry, Collagen Synthesis." StatPearls / NCBI Bookshelf, 2023.
• Holeček M. "Origin and Roles of Alanine and Glutamine in Gluconeogenesis in the Liver, Kidneys, and Small Intestine under Physiological and Pathological Conditions." PMC / International Journal of Molecular Sciences, 2024.
• König D et al. "Potential Relevance of Bioactive Peptides in Sports Nutrition." PMC / Nutrients, 2021.
• Review: "The role and application prospects of plant-derived bioactive peptides in exercise fatigue recovery." Frontiers in Nutrition, 2026.
• Zhou S et al. "Increased Collagen Synthesis Rate during Wound Healing in Muscle." PMC / PLOS ONE, 2013.
• Study of Biological Activity of Lys-Glu-Asp-Trp-NH2 Endogenous Tetrapeptide. ResearchGate, 2010.
• Ala-Leu overview. ScienceDirect Topics.
• Ala-Lys dipeptide: Topics by Science.gov.
• US Patent 6727227: Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application. USPTO.
• Jacobs PL. "Safety and organ health with 8 weeks use of commercially available bio-active peptide supplement: A prospective, double-blind, placebo controlled randomized trial." PMC / Journal of the International Society of Sports Nutrition, 2015.